Minretumomab Biosimilar, Anti-human TAG-72 Monoclonal Antibody | C052P

Catalog No.	C052P
Product Name	Minretumomab Biosimilar, Anti-human TAG-72 Monoclonal Antibody | C052P
Supplier Name	Syd Labs, Inc.
Brand Name	Syd Labs
Synonyms	B29, IGB, Ig-beta
Summary	Recombinant Humanized IgG1 Monoclonal Antibody.
Source/Host	The anti-human CD79B monoclonal antibody polatuzumab biosimilar was produced in mammalian cells.
Specificity/Sensitivity	The in vivo grade polatuzumab biosimilar specifically binds to the human CD79B protein.
Applications	ELISA, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by Polatuzumab.
Form Of Antibody	0.2 uM filtered solution, pH 7.4, no stabilizers or preservatives.
Endotoxin	< 1 EU per 1 mg of the protein by the LAL method.
Purity	>95% by SDS-PAGE under reducing conditions and HPLC.
Shipping	The research grade polatuzumab biosimilar is shipped with ice pack. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage	Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70°C as supplied. 1 month from date of receipt, 2 to 8°C as supplied.
Note	The research grade polatuzumab biosimilar protein is for research use only (RUO). Recombinant human IgG1 isotype controls are available. Condition of sample preparation and optimal sample dilution should be determined experimentally by the investigator.
Order Offline	Phone: 1-617-401-8149 Fax: 1-617-606-5022 Email: message@sydlabs.com Orleave a message with a formal purchase order (PO) Or credit card.

Description

C052P: Polatuzumab Biosimilar, Human CD79B Monoclonal Antibody

Recombinant Humanized IgG1 Monoclonal Antibody.

Background

What is polatuzumab biosimilar research grade? Polatuzumab is a humanized IgG1-kappa monoclonal antibody against the human CD79B protein, which is ubiquitously expressed on the surface of malignant B cells. Polatuzumab vedotin is used to treat diffuse large B-cell lymphoma (DLBCL) after at least two other cancer treatments did not work or have stopped working. It is given in combination with bendamustine (Bendeka, Treanda) and a medicine that contains rituximab (Rituxan). Polatuzumab vedotin works by attaching to CD79b and releasing a toxic substance that kills the cancer cells. Polatuzumab biosimilar uses the same protein sequences as the therapeutic antibody polatuzumab.

Syd Labs provides the following research grade antibody biosimilars used in ADCs:
Tusamitamab biosimilar, research grade, anti-human CEACAM5 monoclonal antibody
Rovalpituzumab biosimilar, research grade, anti-human DLL3 monoclonal antibody
Trastuzumab biosimilar, research grade, anti-human HER2 monoclonal antibody
Cofetuzumab biosimilar, research grade, anti-human PTK7 monoclonal antibody
Ifinatamab biosimilar, research grade, anti-human B7-H3 (CD276) monoclonal antibody
Sacituzumab biosimilar, research grade, anti-human Trop-2 monoclonal antibody
Gemtuzumab biosimilar, research grade, anti-human CD33 monoclonal antibody
Polatuzumab biosimilar, research grade, anti-human CD79B monoclonal antibody
Cetuximab biosimilar, research grade, anti-human EGFR monoclonal antibody

Please remember our product information: Polatuzumab Biosimilar, Human CD79B Monoclonal Antibody: C052P Syd Labs

No more offers for this product!